Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhinoial is a Class IIa medical device nasal spray developed by Ricerfarma for the treatment and repair of the nasal mucosa. Its primary active ingredient is high-molecular-weight sodium hyaluronate, which works by forming a mucoadhesive, hydrating film over the nasal lining. This protective barrier is further enhanced by glycerophosphocholine and aloe leaf juice polysaccharides to provide long-lasting hydration and support tissue repair. It is indicated for symptoms associated with rhinitis, allergic rhinitis, and acute or chronic sinusitis, including nasal dryness, irritation, and blockage. Unlike pharmacological decongestants, Rhinoial is non-pharmacological and suitable for prolonged use without rebound effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rhinoial.